Anlon Healthcare Limited (AHCL) — Financial Results

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Anlon Healthcare Limited announced its investor presentation for Q4 and FY26, highlighting strategic acquisitions of Bizotic Lifescience and Apiqo Organics to accelerate capacity expansion and growth. The company now operates with 1,400-1,600 MTPA installed capacity, up from 400 MTPA, and projects ~30% revenue CAGR over three years. Financials show revenue growth to ₹172.22 crores in FY26 from ₹66.58 crores in FY24, with PAT reaching [amount context mismatch] crores. The presentation details regulatory approvals, global presence across 15 countries, and focus on API, intermediate, and nutraceutical segments. Key growth drivers include backward integration, new API launches, and expansion into industrial chemicals, supported by strong DMF filings and regulatory credentials.

2 Financial Results Neutral 📄 PDF

📢 Key Event
Audio recording of Q4 FY26 earnings call made available

💡 Investor Takeaway
Investors can now access the full audio of the recent earnings discussion.

Anlon Healthcare Limited announced the audio recording of its Q4 FY26 earnings conference call held on June 3, 2026 at 4:00 PM IST, now available on its investor relations website at https://www.anlon.in/reports.php?subid=15&name=Investor-Meet.

📊 Stock Analysis — AHCL ✨ Ask AI About This